Abivax (ABVX) is presented as a top pick with the potential to reach $200 per share, driven by a drug that could become one of the biggest in pharmaceutical history. Another high-conviction opportunity is Sarepta Therapeutics (SRPT), which has an upcoming drug data release for LGMD that could potentially double the stock price to $30. For a more speculative play, Precigen (PGEN) faces a key drug approval decision in two weeks that could cause the stock to re-rate significantly higher. On the short side, the entire public quantum computing sector is viewed skeptically, with D-Wave (QBTS) highlighted as the best short opportunity due to missing revenue guidance. While the long-term outlook for NVIDIA (NVDA) is strong, investors should monitor short-term risks from increasing competition and the health of its key customers.

Here are the investment insights from the podcast transcript.

NVIDIA (NVDA)

The discussion around NVIDIA presented both bullish and bearish arguments, suggesting a complex outlook for the stock.

• Bearish Signals:
  • Customer Weakness: CoreWeave, a major NVIDIA customer and a "high flyer" stock, was down significantly (over 10%). This is seen as a potential warning sign for NVIDIA's business.
  • Competitive Pressure & Delays: A research report from Fubon Securities was mentioned, suggesting that NVIDIA's next-generation Rubin (R100) chip is being redesigned and potentially delayed to better compete with AMD's upcoming MI450 chip.
  • Increased Competition: The speaker noted that there are new inference chips coming to market from competitors, which could threaten NVIDIA's dominance. There was also a mention of a conference call where a company stated they have "many options for inference chips," which is not a bullish sign for NVIDIA.
• Bullish Signals:
  • Unprecedented Demand: Despite potential headwinds, the speaker emphasized that demand for NVIDIA's products remains "unprecedented."
  • Long-Term Vision: When addressing valuation concerns, the speaker stated to "get ready for $10 trillion," indicating a very strong long-term bullish conviction.
  • Product Pipeline: The discussion highlighted the roadmap including the current Blackwell architecture and the future Rubin platform, suggesting continued innovation.

Takeaways

• Investors should monitor the performance of key NVIDIA customers like CoreWeave, as their financial health can be a leading indicator for NVIDIA's sales.
• The competitive landscape is heating up, particularly with AMD. Any confirmed delays or redesigns of NVIDIA's future chips (Rubin) to counter competition could impact sentiment.
• The long-term bull case is tied to the continued, massive demand for AI chips, which is expected to overcome short-term competitive threats and justify a much higher valuation. The speaker seems to believe the bull case will ultimately win out.

Quantum Computing Sector

The speaker expressed a strong bearish sentiment across the entire public quantum computing sector, viewing it as highly speculative and far from commercial viability. He mentioned he has something "downright diabolical" planned for the sector, implying a potential detailed short report or thesis is forthcoming.

• D-Wave Quantum (QBTS):
  • Labeled the "best short in quantum."
  • The reasoning is that the company guided for revenue, but "the opposite is happening," making it a "pretty clear short."
• IonQ (IONQ):
  • Criticized for "intolerable" levels of promotion, including ventures into "quantum networking" and buying a space company.
  • The speaker believes the company has "all kinds of other issues."
• Rigetti Computing (RGTI):
  • The speaker sarcastically referred to their earnings call as "super bullish" and that "everyone on Wall Street's talking about it," strongly implying the opposite was true and the results were poor.
• Quantum Computing Inc. (QUBT):
  • Dismissed as a "weird, you know, non-company company."

Takeaways

• The speaker is extremely skeptical of the current state of quantum computing companies, believing they lack viable products and revenue.
• D-Wave (QBTS) was identified as the most compelling short opportunity due to its failure to meet revenue expectations.
• Investors should be wary of the promotional language used by companies like IonQ and view the entire sector with extreme caution until there is clear evidence of commercial progress and revenue generation. The speaker's analysis suggests the technology is decades away from practical use cases like breaking encryption.

Sarepta Therapeutics (SRPT)

The speaker is very bullish on Sarepta and holds it as a massive 32% of his personal portfolio, though he acknowledges the need to trim the position due to its size.

• Core Thesis: The stock was a great value when he bought it around $13 (at "one times earnings") and remains attractive now (at "two times earnings"). He believes there is "still a lot of upside."
• Upcoming Catalyst: The speaker highlighted upcoming data for the company's limb-girdle muscular dystrophy (LGMD) drug as a major potential catalyst that could "double the stock or get us up to $30."
• Positive Developments:
  • A rumor that Sirolimus is being used successfully with Sarepta's therapy was mentioned as a significant positive if true.
  • The company resolved a potential cash crunch by paying a partner (Arrowhead) with stock instead of cash, which is seen as a bullish sign of financial strength.
• Portfolio Management:
  • Despite his bullishness, the speaker is actively looking to reduce his oversized position. He mentioned selling 20% of his holdings around $19.50 and would consider selling more at $25.

Takeaways

• Sarepta has a significant near-term catalyst in its upcoming LGMD drug data, which could lead to a substantial stock price increase.
• The company's valuation is still considered reasonable, and recent financial maneuvers have de-risked the balance sheet.
• While the fundamental outlook is strong, investors should be mindful of position sizing. The speaker's own plan to trim suggests that taking some profits after a large run-up can be a prudent strategy.

Abivax (ABVX)

Abivax is another of the speaker's high-conviction bullish picks, representing a 50% position in his portfolio. The thesis is based on the drug's potential and the CEO's track record.

• Blockbuster Potential: The core argument is that for a ~$5 billion valuation, an investor gets a drug that could become "one of the biggest drugs in pharmaceutical history," with the potential for $5 billion in annual revenue. The speaker calls it a "no-brainer."
• Price Target / Buyout: He stated the stock could hit $200 "pretty easily." He also speculated that a larger company like Novartis might acquire Abivax for ~$15 billion, representing a 3x return from current levels.
• CEO Confidence: The speaker has immense trust in CEO Mark DeGarardel, whom he knows personally and praises for his past success in selling a company to Novo Nordisk for around a billion dollars.
• Investor Psychology: He advises investors to ignore the fact that the stock has already run up significantly. The focus should be on the fundamental value ("what is this thing worth?"), not the past price on a chart.

Takeaways

• The investment case for Abivax is a classic high-risk, high-reward biotech play based on the massive potential of a single drug asset.
• The CEO's strong track record in creating shareholder value is a key part of the bullish thesis.
• This is a long-term, fundamental bet. Investors should focus on the drug's potential peak sales and the possibility of a strategic buyout, rather than short-term price movements.

Precigen (PGEN)

The speaker analyzed Precigen as an interesting, potentially "underloved" biotech stock with a near-term catalyst.

• Background: This company is the successor to Intrexon (XON), a company with a poor reputation on Wall Street, which may be causing the stock to be overlooked.
• The Drug & Disease: The company has a gene therapy for Recurrent Respiratory Papillomatosis (RRP), a serious condition caused by HPV.
• Bullish Case:
  • The clinical trial was conducted at the NIH, lending it credibility with the FDA.
  • The data appears strong, showing a ~50% complete response rate (defined as no need for surgery for 12 months), which is a dramatic improvement for patients who previously required multiple surgeries per year.
  • The speaker believes the data is strong enough for approval ("I would approve this drug").
• Risks:
  • The definition of "complete response" is based on avoiding surgery, which is a softer endpoint than tumor shrinkage and could potentially be manipulated.
  • The company's legacy as Intrexon and its association with RJ Kirk means it is "hated on Wall Street."

Takeaways

• PGEN presents a speculative opportunity with a binary event in two weeks (the PDUFA date for its RRP drug).
• The bull case rests on strong clinical data from a reputable institution (NIH) for a disease with high unmet need.
• The bear case is rooted in the company's poor historical reputation and questions around the trial's primary endpoint. If the drug is approved, the stock could re-rate significantly as the market overcomes its historical bias.

Other Notable Mentions

• aTyr Pharma (ATYR): The speaker mentioned having a 60% portfolio position in this stock, indicating extreme conviction, but did not elaborate on the specific investment thesis.
• Oklo (OKLO): Used as an example of market froth and speculation, highlighting its $12 billion market cap with "not a stitch of revenue."
• Coherent (COHR): An NVIDIA supplier whose stock dropped 14% after what was described as an "uninspiring" earnings report. This was seen as a potential negative indicator for the semiconductor supply chain.
• Joby Aviation (JOBY): The speaker holds a "small short position" but admitted to not following the company closely.
• Tesla (TSLA): Described as a "battleground stock" that the speaker is avoiding (neither long nor short).
• Humocyte (HUMA) & Inmune (INMB): Mentioned as potential short ideas due to low revenue (Humocyte) or being a "decent short" (Inmune).